Climb Bio (NASDAQ:CLYM) Given New $15.00 Price Target at HC Wainwright

Climb Bio (NASDAQ:CLYM) had its target price hoisted by HC Wainwright from $11.00 to $15.00 in a research note published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts have also commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Climb Bio in a research note on Wednesday, January 21st. Robert W. Baird increased their target price on Climb Bio from $9.00 to $12.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. Wedbush began coverage on Climb Bio in a research report on Thursday, March 5th. They issued an “outperform” rating and a $12.00 price target on the stock. Finally, Piper Sandler assumed coverage on Climb Bio in a research note on Friday, February 13th. They issued an “overweight” rating for the company. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.40.

Climb Bio Trading Up 1.1%

Shares of CLYM opened at $7.33 on Tuesday. Climb Bio has a 12 month low of $1.05 and a 12 month high of $8.04. The firm’s 50 day moving average is $5.32 and its 200-day moving average is $3.40. The stock has a market capitalization of $499.76 million, a PE ratio of -8.24 and a beta of -0.25.

Climb Bio (NASDAQ:CLYM) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). Equities research analysts predict that Climb Bio will post -1.57 earnings per share for the current fiscal year.

Insider Transactions at Climb Bio

In other news, Director Ra Capital Management, L.P. acquired 213,099 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The shares were acquired at an average cost of $2.18 per share, with a total value of $464,555.82. Following the completion of the purchase, the director directly owned 3,294,856 shares of the company’s stock, valued at $7,182,786.08. The trade was a 6.91% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have purchased 321,672 shares of company stock valued at $779,626 over the last quarter. Company insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Climb Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC acquired a new stake in shares of Climb Bio in the 1st quarter valued at $27,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Climb Bio during the 3rd quarter worth $29,000. Qube Research & Technologies Ltd bought a new stake in shares of Climb Bio during the 2nd quarter worth $43,000. Virtu Financial LLC acquired a new stake in Climb Bio in the fourth quarter valued at about $43,000. Finally, Blair William & Co. IL acquired a new stake in Climb Bio in the fourth quarter valued at about $44,000. 69.76% of the stock is currently owned by institutional investors.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.